S.Biomedics
S.Biomedics is a Seoul-based clinical-stage biotech developing TED-A9, an investigational cell therapy for Parkinson's disease. The KOSDAQ-listed company partners with Catalent for GMP manufacturing and clinical progression toward potential commercialization.
- Company typePrivate
- Founded2005
- HeadquartersSeoul, South Korea
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
S.Biomedics firmographics
Firmographics- Name
- S.Biomedics
- Legal name
- S.Biomedics
- Website
- https://sbiomedics.com
- Company type
- Private
- Founded year
- 2005
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- S.Biomedics is a Seoul-based clinical-stage biotech developing TED-A9, an investigational cell therapy for Parkinson's disease. The KOSDAQ-listed company partners with Catalent for GMP manufacturing and clinical progression toward potential commercialization.
- Ownership category
- akta.pro rank
S.Biomedics industry classification
Industry- Product category
- Cell Therapy / Regenerative Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Cell Therapy Developers (Autologous) (HLAAABAA)
- akta.pro secondary industry
- Stem Cell–Based Regenerative Therapies (HLAAAGAA)
Keywords
Where S.Biomedics is headquartered
LocationHeadquarters
- HQ city
- Seoul
- HQ country
- South Korea
- HQ region
- Asia
Markets served
S.Biomedics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
S.Biomedics product offering
Product offeringCore offering
S.Biomedics is a clinical-stage biotechnology company developing cell-based therapeutics for regenerative biomedicine. Its core asset is TED-A9, an investigational cell therapy in development for the treatment of Parkinson's disease, supported by a strategic manufacturing partnership with Catalent for clinical development and potential commercialization.
Differentiator
Problem solved
Functional benefit
Products and services
- TED-A9 TED-A9 is an investigational cell therapy for the treatment of Parkinson's disease. It is being developed through a strategic partnership with Catalent to leverage global cell therapy development and GMP manufacturing capabilities, progressing from early development through clinical trials to potential market launch. The therapy is intended for Parkinson's disease patients and the healthcare providers treating them.
Companies that use S.Biomedics
Customer profileSegments1 record
Ideal customer profiles1 record
S.Biomedics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
S.Biomedics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- CatalentcoreCatalent and S.Biomedics entered a strategic partnership to develop and manufacture TED-A9, a cell therapy for Parkinson's disease. Catalent will utilize its global capabilities in cell therapy development and GMP manufacturing to support S.Biomedics' pipeline. The collaboration aims to accelerate the therapy's progress from early development through clinical trials and market launch. This partnership provides S.Biomedics with access to established manufacturing infrastructure and regulatory expertise for cell therapy commercialization.
S.Biomedics competitors and assessment
Company assessmentRegional players
- JW Therapeutics: China-based cell therapy company developing CAR-T and other cell therapies, a relevant regional peer for S.Biomedics in the broader Asia cell therapy ecosystem.
- Medipost: Korean KOSDAQ-listed cell therapy company (developer of Cartistem) operating in regenerative medicine, comparable to S.Biomedics as a regional cell therapy peer in the same Korean market.
- GC Cell (GC Biopharma): Korean biopharmaceutical company with cell therapy and regenerative medicine programs, providing a regional peer benchmark for Korean-listed cell therapy developers.
Direct peers
- BlueRock Therapeutics: A Bayer-owned cell therapy company developing dopaminergic neuron cell therapies for Parkinson's disease, the most directly comparable clinical-stage competitor to S.Biomedics' TED-A9 program.
- Aspen Neuroscience: Clinical-stage company developing autologous iPSC-derived cell therapies for Parkinson's disease, directly competing in the same indication and modality as TED-A9.
Emerging players
- Sana Biotechnology: Clinical-stage cell and gene therapy company with platform technology applicable to CNS indications including Parkinson's, an emerging peer in cell-based regenerative medicine.
Broad incumbents
- Novo Nordisk: Global pharmaceutical company that has publicly disclosed cell therapy ambitions in Parkinson's disease through partnerships and acquisitions, representing a large-cap incumbent with the resources to compete across modalities.
- Sumitomo Pharma: Large Japanese pharmaceutical company developing an iPSC-derived cell therapy for Parkinson's disease (with partners including Kyoto University), representing a broader-cap, better-funded competitor in the same therapeutic niche.
Others
- Catalent: S.Biomedics' strategic manufacturing partner and a leading global CDMO for cell therapies, comparable as an ecosystem participant enabling cell therapy commercialization rather than as a direct competitor.
- Prevail Therapeutics (Eli Lilly): Lilly-owned gene therapy company historically focused on Parkinson's disease and other neurodegenerative disorders, thematically related as a CNS modality peer in the Parkinson's treatment space.
Market position
Customer concentration
S.Biomedics social profiles
Digital presenceS.Biomedics financial estimates
Financial estimateRevenue estimate
Valuation estimate
S.Biomedics leadership team
Management profileNumber of profiles
Profiles1 record
S.Biomedics funding detail
Funding detailFunding overview
Funding rounds1 record
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
S.Biomedics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about S.Biomedics
What does S.Biomedics do?
S.Biomedics is a clinical-stage biotechnology company developing cell-based therapeutics for regenerative biomedicine. Its core asset is TED-A9, an investigational cell therapy in development for the treatment of Parkinson's disease, supported by a strategic manufacturing partnership with Catalent for clinical development and potential commercialization.
Is S.Biomedics a public or private company?
S.Biomedics is a private company. It is classified as public and is currently operating.
When was S.Biomedics founded?
S.Biomedics was founded in 2005. It employs 11 to 50 people.
Where is S.Biomedics based?
S.Biomedics is headquartered in Seoul, South Korea, in the Asia region.
Who are S.Biomedics's main competitors?
Regional players on record are JW Therapeutics, Medipost and GC Cell (GC Biopharma). Direct peers are BlueRock Therapeutics and Aspen Neuroscience. Sana Biotechnology is listed as an emerging player. Broad incumbents are Novo Nordisk and Sumitomo Pharma. Others are Catalent and Prevail Therapeutics (Eli Lilly).
Does S.Biomedics have an API?
No public API is recorded for S.Biomedics.
What industry is S.Biomedics in?
S.Biomedics's product category is Cell Therapy / Regenerative Biopharmaceuticals. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous), with a secondary code of HLAAAGAA, Stem Cell–Based Regenerative Therapies. Its NAICS code is 325414 and its SIC code is 2836.